SELLAS Releases Annual Letter to Shareholders

Ads

You May Also Like

FDA approves Roche’s Hemlibra for haemophilia A without factor VIII inhibitors

First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based ...

RENNOVA HEALTH REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

WEST PALM BEACH, Fla, June 19, 2018 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTCQB: ...

Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES

PRESS RELEASE: REGULATED INFORMATION9 October 2018, 07:00 CESTDisclosure of Outstanding Voting Securities Mechelen, Belgium, ...